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C E L L  B I O L O G Y
Mechanisms of nuclear content loading to exosomes
Akira Yokoi1*, Alejandro Villar-Prados1,2*, Paul Allen Oliphint3, Jianhua Zhang4, Xingzhi Song4, 
Peter De Hoff5, Robert Morey5,6, Jinsong Liu7, Jason Roszik4,8, Karen Clise-Dwyer9, Jared K. Burks10, 
Theresa J. O’Halloran3, Louise C. Laurent5,6, Anil K. Sood1,11†
Exosome cargoes are highly varied and include proteins, small RNAs, and genomic DNA (gDNA). The presence of 
gDNA suggests that different intracellular compartments contribute to exosome loading, resulting in distinct 
exosome subpopulations. However, the loading of gDNA and other nuclear contents into exosomes (nExo) remains 
poorly understood. Here, we identify the relationship between cancer cell micronuclei (MN), which are markers of 
genomic instability, and nExo formation. Imaging flow cytometry analyses reveal that 10% of exosomes derived 
from cancer cells and <1% of exosomes derived from blood and ascites from patients with ovarian cancer carry 
nuclear contents. Treatment with genotoxic drugs resulted in increased MN and nExos both in vitro and in vivo. 
We observed that multivesicular body precursors and exosomal markers, such as the tetraspanins, directly inter-
act with MN. Collectively, this work provides new insights related to nExos, which have implications for cancer 
biomarker development.
INTRODUCTION
Exosomes are small extracellular vesicles that mediate biological and 
cellular functions including cell-to-cell communication (1). Exosomes 
are generated in early endosomes and then stored in multivesicular 
bodies (MVBs) that fuse with the plasma membrane and release the 
exosomes to the extracellular space (2). Tetraspanins, proteins known 
as major exosomal markers, that localize to endosomes, MVBs, and 
exosomes are thought to be responsible for trafficking cargo into 
these organelles (3). The ability of exosomes to induce distinct bio-
logical behaviors in either the cells that secrete them or the recipient 
cells depends on their cargo (4). Exosome cargoes are variable and 
can include proteins and RNA species (5). The presence and abun-
dance of protein and RNA, including microRNAs, can influence cell 
behavior in several contexts, ranging from immune system activation 
to suppression of solid tumor growth and cancer metastasis (6).
Recent studies have demonstrated the presence of genomic DNA 
(gDNA) and nuclear proteins within exosomes (7). The presence of 
gDNA in exosomes has been associated with processes such as cell 
senescence and stimulation of the cGAS/STING inflammatory path-
way (8). In addition, gDNA is predominantly detected in exosomes 
derived from cancer cells rather than healthy cells. Paradoxically, 
gDNA is mainly confined to the cell nucleus and does not normally 
interact with the cytoplasmic MVBs that give rise to exosomes (9). 
Thus, the mechanisms by which nuclear components are present in 
exosomes remain poorly understood.
One possibility involves micronuclei (MN), which are cyto-
plasmic structures enveloped by a nuclear membrane and are generated 
when the cell nucleus fails to properly segregate nuclear material, 
including chromosomes. (10). This mis-segregation can arise during 
mitosis and can be driven by DNA-damaging agents, such as radia-
tion, which can result in chromosome fragmentation (11). The pres-
ence of MN serves as a surrogate marker of genomic instability, 
which is a hallmark of cancer (12). The nuclear envelope that sur-
rounds MN is highly unstable, eventually breaking down and expos-
ing its contents to the cytoplasm during cell division (13). Induction 
of MN formation can promote activation of the cGAS/STING path-
way, resulting in an inflammatory response against both senescent 
and cancer cells (14).
Here, we identify a previously unidentified interaction between 
MN and nExo. We show that induction of MN formation using geno-
toxic drugs promotes nExo release. Our results suggest a mechanism 
for the origin of gDNA in exosomes whereby, following MN collapse, 
their nuclear contents are shuttled into MVBs via tetraspanins. 
Moreover, we found that exosomal gDNAs in ovarian cancer pa-
tients reflect copy number variation (CNV) status of the primary 
tumor, revealing informative DNA mutations. Thus, nExos can 
serve as important biomarkers for cancer detection and longitudinal 
monitoring of cancer patients.
RESULTS
Ovarian cancer exosomes contain nuclear content
Despite the prevalence of gDNA in cancer-derived exosomes, the 
relationship between genomic instability and the abundance of nExo 
has not been elucidated. To address this problem, we screened The 
Cancer Genome Atlas (TCGA) to determine which tumor types have 
the highest number of chromosomal duplications and are thus the 
most genomically unstable (Fig. 1A). Of the 25 tumor types investi-
gated, we observed that high-grade serous ovarian cancer (HGSC) 
ranked fourth highest in median ploidy and the genome was char-
acterized as highly unstable, which has been associated with poor 
clinical outcomes (15).
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Fig. 1. Characterization of nuclear-derived content from ovarian cancer exosomes. (A) TCGA pan-cancer ploidy analysis of 20 cancer types. n = 62 [kidney chromo-
phobe (KICH)], n = 418 [brain low-grade glioma (LGG)], n = 7 [pancreatic cancer (PAAD)], n = 138 [pheochromocytoma (PCPG)], n = 353 [prostate adenocarcinoma (PRAD)], 
n = 184 [thyroid carcinoma (THCA)], n = 543 [glioblastoma (GBM)], n = 415 [kidney clear cell carcinoma (KIRC)], n = 61 [uveal melanoma (UVM)], n = 415 [uterine endome-
trial carcinoma (UCEC)], n = 257 [skin cutaneous melanoma (SKCM)], n = 501 [head and neck squamous carcinoma (HNSC)], n = 155 [kidney papillary carcinoma (KIRP)], 
n = 330 [stomach adenocarcinoma (STAD)], n = 940 [breast cancer (BRCA)], n = 187 [liver hepatocellular carcinoma (LIHC)], n = 396 [colon adenocarcinoma (COAD)], n = 34 
[cervical cancer (CESC)], n = 85 [adrenocortical carcinoma (ACC)], n = 158 [renal adenocarcinoma (READ)], n = 435 [lung squamous carcinoma (LUSC)], n = 544 [ovarian cancer 
(OV)], n = 429 [lung adenocarcinoma (LUAD)], n = 144 [bladder cancer (BLCA)], and n = 55 [uterine carcinosarcoma (UCS)]. (B) Cryo-EM image of the exosomes isolated 
from OVCAR-5 cells. Scale bars, 100 nm. (C) NTA for the exosomes isolated from OVCAR-5 cells. (D) Western blot analysis of exosome markers in OVCAR-5. TSG101, Alix, 
and CD63 are used as exosome markers, and GRP94 is used as a marker of cellular contamination. TCL, total cell lysate. (E) Pie chart of cellular compartment proteins re-
sulting from MS analysis in OVCAR-5 cell–derived exosomes. Nuclear components are highlighted in red: 1, endoplasmic reticulum; 2, endosome; 3, Golgi; 4, cell surface; 
5, mitochondrion; 6, proteasome; 7, vacuole; 8, spliceosomal complex. (F) Counts of the cellular compartment origin of proteins resulting from MS analysis in OVCAR-5 
cell–derived exosomes. The x axis represents the categories of cellular compartments. Nuclear proteins identified in chromosome and nucleus are highlighted in red. 
(G) CNVs of both the exosomal DNA (inner red circle) and cellular DNA (outer blue circle), both derived from OVCAR-5 cells, are displayed on a chromosome map generated 
using Circos (v0.69.3). The outermost circle represents human chromosomes with coordinates (megabases). The green and red histograms inside the blue and red inner 
circles represent copy number alterations identified by cnvkit. The larger the bar on the track, the larger the copy number alteration (log scale). Green bars represent 
amplification events, and red bars represent deletions. (H) A Venn diagram of all the CNVs overlapping between the exosomal and cellular DNA derived from OVCAR-5 
cells. (I) Representative plots of OVCAR-5 exosomes from flow cytometry analysis. Top left: Particles are shown as black dots, and exosomes are in the green area. Right: 
Each dot indicates single exosomes stained with CellMask Green (Ch02), and the red gate indicates DNA-positive particles stained with DRAQ5 (Ch11). Bottom left: 
Snapshots of individually stained exosomes. (A) and (B) are the exosomes present in the areas indicated in the right panel. (A) represents the DNA-positive exosomes, and 
(B) represents the negative exosomes. (J) Representative gate images of OVCAR-5 exosomes from imaging flow cytometry analysis. Left: Each green dot indicates 
a single exosome, and the blue gate indicates a Lamin A/C–positive population. Right: All dots are from DNA-positive exosomes, and the green gate indicates a Lamin 
A/C–positive population.
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Using HGSC preclinical models, we first tested the purity of our 
exosome isolation approach with cryo–electron microscopy (cryo-EM), 
nanoparticle tracking analysis (NTA), and immunoblotting assays 
(Fig. 1, B to D, and fig. S1, A to C). To determine whether the exo-
somes carried nuclear proteins, we performed a mass spectrometry 
(MS) analysis on the exosomal fractions. In the exosomes isolated 
from OVCAR-5 (OVCAR-5exo) cells, an HGSC cell line, 201 nuclei- 
associated proteins and 17 chromosome-associated proteins were 
detected, and 12.5% of the total number of detected proteins were 
nuclear-derived (Fig. 1, E and F).
On the basis of these findings, we next used whole-genome 
sequencing (WGS) to compare CNV between the DNA from 
OVCAR-5 cells and exosomes (Fig. 1G). The CNVs were quite similar 
between the cell and exosome DNA (Fig. 1H). While some studies 
have shown that gDNA is present in exosomes (7, 9), the subpopula-
tion of exosomes that contain DNA and the amount of exosomes 
that contain DNA are unclear. To address this question, we used 
the Amnis Image Stream X, MkII flow cytometer, which can detect 
single exosomes as previously described (16). We adapted this 
methodology to analyze nExo by first staining our exosomes with the 
CellMask plasma membrane stain and loading onto the flow analyzer. 
Beads of various sizes were used as reference to set the gates for the 
exosome population (Fig. 1I, left upper panel, and fig. S1, D to F). 
The particles with a side-scatter (SSC) aspect ratio close to 1 were 
specifically selected to exclude exosome aggregates from our analysis 
(fig. S1G). To confirm that the particles detected were bound by 
lipid membranes, exosomes were treated with 0.5% NP-40 to disrupt 
the membrane. This almost completely abolished the presence of 
detected exosomes (fig. S1H). Furthermore, exosome concentration 
positively correlated (R2 = 0.968) with the particles detected by the 
analyzer (fig. S1I). These results demonstrate the successful detection 
of exosomes by our imaging flow cytometry method. In addition, 
we confirmed that this method can be used for exosome analysis 
without the procedure of exosome isolation because it detected exo-
somes by using cell culture medium (fig. S1J).
To identify the presence of gDNA and to quantify the percentage 
of DNA-positive exosomes, the exosomes were stained with DRAQ5, 
a dye that preferentially binds double-stranded DNA (dsDNA) 
and is cell permeant to allow quantification of the percentage of 
DNA-positive exosomes (Fig. 1I). In addition, our single-particle 
imaging flow cytometry method allowed quantification of subpopula-
tions of DNA-positive exosomes that were also positive for other 
exosome protein markers, such as tetraspanins (Fig. 1I and fig. S2A). 
CD9 and CD63, well-documented exosome markers, were abun-
dantly detected in both DNA-positive and DNA-negative exosomes 
(fig. S2A). To confirm the intra-exosomal localization of DNA, exo-
somes were treated with deoxyribonuclease (DNase) I to degrade 
DNA attached to the outer membrane of exosomes. There was 
approximately a 50% reduction in DNA-positive exosomes after 
DNase I treatment (fig. S2B). These results suggest that gDNA is 
present on both the surface and the inside of exosomes. In addition 
to gDNA, we also tested exosomes for the presence of Lamin A/C, a 
nuclear envelope protein that was present in our OVCAR5-exo MS 
data (Fig. 1, E and F). We observed that Lamin A/C was also detect-
able by flow cytometry (Fig. 1J). This result was further validated by 
detection of Lamin A/C from isolated exosomes via Western blot 
(fig. S2C). Contrary to gDNA, Lamin A/C was not as abundant 
in OVACR5-exo, but we did observe that more than 50% of DNA- 
positive exosomes were also positive for Lamin A/C (Fig. 1J and 
fig. S2D). Other nuclear proteins, such as importin, Nesprin-2, 
and Lamin B1, were also detected in DNA-positive exosomes via 
flow cytometry in OVCAR5-exo, but their abundance was more 
variable (fig. S2E).
Induction of MN increases the population of  
DNA-carrying exosomes
Similar to the presence of gDNA in cancer-derived exosomes, MN 
are also more prevalent in cancer cells due to their inherent genomic 
instability (10). On the basis of this idea, we investigated whether 
any relationship existed between the presence of MN and nExo. We 
first determined the baseline number of cells containing MN in pri-
mary healthy fallopian tube epithelial (FTE) cells compared to ovarian 
cancer cell lines. In primary FTE cells, considered to be the cell of 
origin for many HGSCs (17), the prevalence of MN-containing cells 
was 1% (Fig. 2, A and B). In contrast, about 4% of ovarian cancer 
cells contained MN (Fig. 2, A and B). Comparing the amount of 
nExo secreted by healthy and cancerous cells, we found that cancer 
cells secreted a significantly higher population of nExo (FTEexo, 
0.12 ± 0.04%; OVCAR-5exo, 8.26 ± 1.62%; and OVCAR-8exo, 
8.25 ± 2.61%) (Fig. 2, C and D). These data suggest that cells with 
high genomic instability and therefore increased MN, such as cancer 
cells, secrete a larger number of nExos.
To further test our hypothesis, we treated ovarian cancer cells 
with the genotoxic drugs topotecan (10 nM) or olaparib (20 M) to 
induce the formation of MN. Upon treatment with either drug, the 
number of MN increased significantly (Fig. 2, E and F, and fig. S3A). 
Similarly, the population of exosomes containing gDNA (Fig. 2, 
G and H, and fig. S3, B and C) and nuclear proteins (fig. S3D) was 
also increased after treatment with these drugs. These results indi-
cate that inducing genomic instability increases MN production and 
subsequently increases nExo abundance.
To validate these findings in vivo, we used the OVCAR-5 ovarian 
cancer model, which represents disseminated peritoneal disease. 
As shown in the schematic diagram (Fig. 3A), each tumor-bearing 
mouse was treated with the maximum tolerated dose of topotecan 
(7.5 mg/kg) and euthanized 48 hours later (18). Tumor growth in 
each mouse was confirmed by in vivo imaging (Fig. 3B). To deter-
mine whether topotecan could induce MN formation, as we observed 
in vitro, tumor nodules were harvested, sectioned, and stained with 
hematoxylin and eosin (H&E) and examined via bright light and by 
immunofluorescence (IF) microscopy (Fig. 3, C and D). H&E staining 
confirmed the presence of MN after topotecan treatment (Fig. 3C). 
To calculate the number of MN, multiple IF images of tumor slides 
were taken, and MN were systematically counted by the Vectra–
inForm Image Analysis System (PerkinElmer) (Fig. 3D). There was 
a trend toward increased MN-positive cell percentages in the 
topotecan-treated group versus vehicle control, although this percent-
age was not statistically significant (Fig. 3E).
To measure differences in the amount of nExos produced after 
each treatment, exosomes were isolated from serum and ascites of 
tumor-bearing mice from each group, and their purity was confirmed 
by cryo-EM, NTA, and Western blotting for CD63 (Fig. 3, F to H) 
and quantified by imaging flow cytometry. Tumor-bearing mice 
generally had significantly more nExos in their serum than did the 
non–tumor-bearing mice (P = 0.008) (Fig. 3I). Comparing topotecan- 
treated mice with vehicle control, we observed a significant increase 
of nExos in ascites (P = 0.028) but no difference in the serum nExos 
(Fig. 3, J and K). These results indicate that tumors produce more 
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Fig. 2. Promoting MN formation increases DNA-carrying exosomes. (A) Immunofluorescence (IF) images of FTE and OVCAR-5 cells. The inset shows a magnified image 
of a micronucleated OVCAR-5 cell in the right panel. Scale bars, 50 m. (B) Quantification of MN cells in FTE, OVCAR-5, and OVCAR-8 cells. MN counting is described in 
Materials and Methods. The experiment was performed in three independent biological replicates, and the average of the fold changes was calculated. Error bars are 
represented as SD. Statistical significance was determined by conducting an unpaired Student’s t test. (C) Representative images of FTEexo and OVCAR-5exo from imaging 
flow cytometry analysis. The gates in both graphs indicate the DNA-positive population. (D) Population of DNA-positive exosomes in FTEexo, OVCAR-5exo, and OVCAR-8exo. 
The experiment was performed in three independent biological replicates, and the average of the fold changes was calculated. Error bars represent SD. Statistical significance 
was determined by conducting an unpaired Student’s t test. (E) Representative images of nuclei from OVCAR-5 cells. Nuclei were IF-stained with Lamin A/C antibody. 
Scale bars, 50 m. (F) Quantification of MN cells in OVCAR-5 and OVCAR-8 cells treated with DMSO, topotecan, and olaparib. The experiment was performed in three 
independent biological replicates, and the average of fold changes was calculated. Error bars represent SD. Statistical significance was determined by conducting an 
unpaired Student’s t test. *P < 0.05, **P < 0.01. (G) Representative images of OVCAR-5exo in imaging flow cytometry analysis. (H) Population of DNA-positive exosomes in 
OVCAR-5exo and OVCAR-8exo. Parental cells were treated with DMSO, olaparib, or topotecan for 48 hours. FTEexo, OVCAR-5exo, and OVCAR-8exo indicate exosomes 
derived from FTE, OVCAR-5, and OVCAR-8 cells, respectively. The experiment was performed in three independent biological replicates, and the average of fold changes 
was calculated. Error bars represent SD. Statistical significance was determined by conducting an unpaired Student’s t test. *P < 0.05.
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Fig. 3. In vivo promotion of nExos with genotoxic drugs in ovarian cancer. (A) Schematic protocol for topotecan treatment. (B) Topotecan was administered intraperitoneally. 
All mice were euthanized on day 30. n of vehicle control–treated mice = 4 and n of topotecan-treated mice = 4. (C) Representative image of tumor tissue sections stained 
with hematoxylin and eosin (H&E). Scale bars, 700 m (left panel) and 100 m (middle panel). Black arrowhead indicates MN. (D) Left upper panel: Representative image 
of tumor tissue stained with DAPI and phalloidin. Scale bar, 50 m. Right upper panel: Representative image of cell segmentation with Vectra imaging software. Lower 
panel: Representative image of the detected MN, indicated by white arrowhead. (E) Quantification of MN cells. MN counting is described in Materials and Methods. 
n of vehicle control–treated mice = 3 and n of topotecan-treated mice = 3. Error bars represent SD. Statistical significance was determined by conducting an unpaired 
Student’s t test. (F) Nanoparticle tracking analyses for exosomes derived from plasma and ascites. (G) Representative cryo-EM images of ascites exosomes from OVCAR-5 
intraperitoneal model. Scale bar, 100 nm. (H) Western blot of mouse plasma exosomes (n = 3). (I) Population of DNA-positive exosomes in serum from non–tumor-bearing 
mouse and OVCAR-5 intraperitoneal model. n = each 6. Error bars represent SD. Statistical significance was determined by conducting unpaired Student’s t test. (J) Popu-
lation of DNA-positive exosomes in serum and ascites from the mice treated with topotecan or vehicle. n = ascites, each 3 and serum, each 4. Error bars represent SD. 
Statistical significance was determined by conducting unpaired Student’s t test. (K) Representative images of serum exosome in imaging flow cytometry analysis.
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nExos and that genotoxic drugs promote MN formation in vivo, in-
creasing the amount of nExo release.
MN and nExo share content and interact in live cells
We next compared the relative nuclear protein abundance between 
MN and nExos. MN from OVCAR-5 cells were isolated via sucrose 
gradient ultracentrifugation, and fractions enriched for MN were 
washed and submitted for MS (Fig. 4A) (19). MN enrichment was 
confirmed with 4′,6-diamidino-2-phenylindole (DAPI) staining and 
IF (Fig. 4A). MS analysis of the MN fraction revealed substantial 
similarity between OVCAR-5 MN and nExo protein content, with 
127 proteins overlapping between the two cellular compartments 
(Fig. 4, B and C). Some of these shared nuclear proteins included 
Lamin A/C and Histone H2B as well as some exosome markers such 
as heat shock proteins (Fig. 4C).
Next, we determined whether MN and exosome-associated pro-
teins interact within cells. Confocal imaging of exosome markers such 
as CD63, CD9, and CD81 revealed colocalization of these proteins 
either in the nuclear envelope or inside the MN of ovarian cancer 
cells (Fig. 4, D and E, and fig. S4A). To further explore whether this 
interaction occurred in live cells, we carried out time-lapse imaging 
of cells overexpressing fluorescently tagged nuclear proteins and 
tetraspanins. Both CD9 and CD63 actively interacted with MN in 
OVCAR-5 cells (Fig. 4, F and G, and movies S1 and S2). These find-
ings suggest that both MN and nExos share a high degree of nuclear 
content and that these structures actively interact within living cells.
Cargo of disrupted MN is loaded into exosomes
The envelope of MN is known to be unstable, and upon its collapse, 
MN contents including gDNA are exposed to the cell cytoplasm (13). 
Therefore, we asked whether this collapse can induce the loading of 
MN contents into exosomes. Consistent with previous findings, con-
focal imaging of ovarian cancer cells showed that some MN were not 
surrounded by their nuclear envelope, suggesting MN collapse (Fig. 5, 
A and B, and fig. S4B). Of interest, we observed that tetraspanin pro-
teins, which can serve as markers for MVBs, often surrounded the MN 
with either partial or total nuclear envelope collapse (Fig. 5, A and B). 
These results were verified by transmission electron microscopy (TEM) 
(Fig. 5, C to E). This revealed that, similar to our confocal observations, 
ovarian cancer cells contained collapsed MN (Fig. 5C and fig. S4C).
To address the mechanism behind nuclear content loading into 
exosomes, we hypothesized that collapsing MN directly interact with 
the molecular machinery for exosome biosynthesis. Exosomes are 
initially formed from the intraluminal vesicles of early endosomes and 
are then stored in MVBs (2). These vesicles are then released as exo-
somes to the extracellular space by fusion of MVBs with the plasma 
membrane (2). TEM revealed that MVBs were located near MN and 
early endosomes, and thus could directly interact with collapsing MN 
(Fig. 5, D and E). Further, confocal analysis showed that intact and 
collapsed MN were both positive for EEA1, the early endosome marker 
(Fig. 5F and fig. S4D). However, a recent report indicates that extra-
cellular DNA can be secreted outside of the exosomal pathway via 
amphisomes (20). In accordance with this, we found that MN also 
contained LC3B, an amphisome and autophagosome marker, revealed 
by immunostaining (fig. S4E). In contrast, MN contained less LMAP-1, 
the late endosome/lysosome marker, compared to EEA1 and LC3B 
(fig. S4E). These results suggest that gDNA can be secreted in an 
exosome-dependent or exosome-independent manner, in which collaps-
ing MN can interact with either early endosomes or amphisomes.
To further explore the molecular mechanism driving MN content 
loading into exosomes, we focused on tetraspanins, such as CD63, 
as they are involved in exosome/MVB cargo loading (3). To deter-
mine whether tetraspanins are necessary for loading MN content 
into the endosomes and ultimately into nExos, we knocked down 
CD63 in ovarian cancer cell lines with short hairpin RNA (shRNA). 
After confirmation of CD63 protein knockdown (Fig. 5G), we exam-
ined changes in the number of nExos by flow cytometry. Cells with 
CD63 knockdown secreted fewer nExos than control cells (Fig. 5H), 
indicating that CD63 plays an important role in loading nuclear 
content into nExos. To further explore the role of CD63 in nExo 
loading, immunoprecipitation (IP) experiments were performed. 
CD63 pulldown from OVCAR-5 cell lysates revealed an association 
with DNA and Histone H2B (Fig. 5, I and J). Thus, CD63 can create 
a complex of gDNA and nuclear proteins and may be important for 
DNA loading in exosomes.
Detection of nExo in clinical samples
To explore the clinical relevance of nExo, we isolated exosomes 
from the plasma and ascites of patients with HGSC to characterize 
their exosomal contents (Fig. 6, A and B). Because of the abundant 
immunoglobulin contamination present in exosomes isolated by 
ultracentrifugation from human serum, we purified these exosomes 
using size exclusion chromatography and then performed MS proteomic 
analysis (21). MS analysis demonstrated that, of the total proteins 
identified in patient-derived exosomes, 3.2 to 3.6% were nuclear 
proteins (Fig. 6, C and D, and fig. S5, A to E). MN were also detected 
in human tumor tissues, with a prevalence of 1% micronucleated 
cells per tumor analyzed (Fig. 6, E and F, and fig. S5F). Using flow 
cytometry, <1% of exosomes contained gDNA, which was consistent 
with our in vivo mouse model data (Fig. 3I and fig. S5G).
WGS analysis of advanced-stage HGSC patient samples revealed 
that 43 gene mutations were found in both tumor and nExos derived 
from ascites. Several of these mutated genes are involved in DNA 
repair, e.g., DROSHA, LIG4, MACROD2, SATB1, RASSF6, and BIRC2 
(Fig. 6H) (22–27). In addition, based on the result of read counts, the 
vast majority of DNA in exosomes was genomic in origin rather than 
mitochondrial, and the mutation signature was similar (Fig. 6I and 
fig. S6A). Moreover, ascites exosomes have a CNV similar to the primary 
tumor, but plasma exosomes did not (Fig. 6J and fig. S6, B to D).
DISCUSSION
In this study, we identified and characterized a subpopulation of 
nExos and provided mechanistic insights into the packaging of their 
nuclear content. Our imaging flow cytometry–based method allowed 
accurate quantification of the nExo subpopulation both in vivo and 
in vitro. We identified a link between MN formation and the gener-
ation of nExos upon induction of genomic instability with genotoxic 
drugs. In addition, our results suggest that MN collapse serves as a 
source of nuclear content shuttled into MVB via tetraspanins (fig. S7). 
Last, we identified the presence of MN and nExos in the ascites of 
patients with ovarian cancer, which holds promise for rapid assessment 
of the genomic status of those tumors.
The identification of a nExo subpopulation in preclinical and 
clinical samples is one of the most important findings in this study. 
To our knowledge, this is the first report to quantify this population 
of exosomes using imaging flow cytometry. As described above, 
cancer cells secrete more nExo than normal cells. However, <1% of 
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Fig. 4. MN and nExo contain similar protein content. (A) Representative images of nuclear fraction and MN-enriched fraction. All samples were obtained from OVCAR-5 
cells and stained with DAPI. The white box in the middle image is a magnified view. Scale bar, 50 m. (B) Counts of protein cellular compartment of origin resulting from 
MS analysis in exosome and MN-enriched fraction. Samples were obtained from OVCAR-5 cells. The x axis represents the categories of cell components. Proteins from 
nuclear and chromosome compartments highlighted in yellow. (C) Venn diagram showing overlapping proteins between exosome and MN-enriched fraction. Samples 
were obtained from OVCAR-5 cells. Lamin A/C, Histone H2A/B, importin, and heat shock protein (HSP) 70/90 were included in the overlapped 127 proteins. (D and E) Serial 
confocal images of mCherry-LaminA/C–expressing OVCAR-5 cells. Nuclei were stained with DAPI. CD63 and CD9 were IF-stained with antibodies as described in Materials 
and Methods. Scale bars, 5 m. (F) Representative images from time-lapse imaging in mCherry-LaminA/C–expressing OVCAR-5 cells. Cell membrane was stained with 
CellMask Deep Red. Cells stably expressed green fluorescent protein (GFP)–CD63 by lentiviral infections as described in Materials and Methods. Scale bar, 3 m. 
(G) Representative images of time-lapse imaging in mCherry-Histone H2B–expressing OVCAR-5 cells. Cells were transiently transfected with mEmerald-CD9 plasmid as 
described in Materials and Methods. Scale bar, 4 m.
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Fig. 5. Cargo of disrupted MN is loaded into nExos. (A) Confocal image of OVCAR-5 cells. Nuclei were stained with DAPI, and Lamin A/C and CD63 were IF-stained as 
described in Materials and Methods. Scale bars, 5 m. (B) Serial confocal stack images of OVCAR-5 cells. Nuclei were stained with DAPI, and Lamin A/C and CD9 were 
IF-stained with antibodies as described in Materials and Methods. Scale bars, 10 m (upper panels) and 3 m (lower panels). (C to E) Representative images of TEM of 
OVCAR-5 cells. Black arrowheads indicate the disrupted nuclear envelop of MN. Scale bars, 2 m (C) and 500 nm (D and E). (F) Serial confocal images of OVCAR-5 cells. 
Nuclei were stained with DAPI. IF staining for Lamin A/C and EEA1 was performed with antibodies as described in Materials and Methods. Scale bars, 5 m (upper panel) and 
2.5 m (lower panel). (G) Western blot of OVCAR-5 cells with CD63 knockdown (CD63 KD). CTRL indicates the OVCAR-5 cells transfected with a scramble shRNA sequence. 
Densitometry analysis is quantified in the bar chart. (H) Representative images of exosome from CD63-knockdown OVCAR-5 cells in imaging flow cytometry analysis. 
The fold change of nExo population. The experiment was performed in three independent biological replicates, and the average of fold changes was calculated. Error bars 
represent SD. Statistical significance was determined by conducting an unpaired Student’s t test. (I) The samples of OVCAR-5 cells with IP experiments for CD63 were 
analyzed with 2% agarose gel electrophoresis, and DNAs were visualized by ethidium bromide staining. (J) Western blot of OVCAR-5 cells with IP experiments for CD63. 
CTRL-IP indicates the OVCAR-5 cells treated with negative control immunoglobulin G (IgG) in the Universal Magnetic Co-IP Kit (54002, Active Motif).
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Fig. 6. Detection of nExo in clinical samples. (A and B) NTA for exosomes was derived from plasma and ascites from patients with high-grade serous ovarian carcinoma, 
along with representative cryo-EM images. Scale bars, 100 nm. (C and D) Pie charts of the cellular compartment of origin of proteins based on MS analysis from plasma- and 
ascites-derived exosomes. Nuclear components are highlighted in red. (C) “Others” includes cytoskeleton, mitochondrion, ribosome, and vacuole. (D) “Others” includes 
mitochondrion, nucleus, organelle lumen, ribosome, and vacuole. (E) Representative tissue image of high-grade serous ovarian carcinoma stained with H&E. Black arrowhead 
indicates MN. Scale bars, 100 m. (F) Population of micronucleated cells in high-grade serous ovarian carcinoma tissue. Pretreated tissue slides were obtained and analyzed 
as described in Materials and Methods. Each dot indicates one view for analysis. n = 4. (G) Representative imaging flow cytometry images of exosomes obtained from 
ascites of patients with high-grade serous ovarian carcinoma. (H) Venn diagram showing overlapping exonic mutated genes between tumor and ascites exosomes. Samples 
were obtained from patients with HGSC. DROSHA, LIG4, MACROD2, SATB1, RASSF6, and BIRC2 were included in the 43 overlapping genes. (I) Read counts of all chromosomes 
in plasma- and ascites-derived exosomal DNA and tumor DNA. All three cases were from patients with advanced-stage HGSC. (J) CNV status in gDNA in ascites-derived 
exosomal DNA and corresponding primary tumor from patients with HGSC. Profiles demonstrate somatic chromosomal gains (upper) and losses (lower), as well as normal 
polymorphisms.
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nExo from human plasma and ascites samples contained gDNA, and 
this ratio was consistent with the in vivo mouse model data. On the 
basis of the finding that nontransformed cells release fewer nExos, 
this discrepancy between the proportions of in vitro and in vivo 
DNA-containing exosomes (around 10% and less than 1%, respec-
tively) is not surprising; tumor-derived exosomes in biofluids are likely 
a subset of a much larger population of non–tumor cell–derived exo-
somes. Given the higher secretion of nExo by cancer cells, the presence 
and quantity of nExos could serve as a cancer biomarker. In addi-
tion, the gDNA in nExos can be interrogated for tumor-associated 
genetic alterations. Cell-free DNA (cfDNA) is a potential biomarker 
for cancer patients (28) and some studies suggest that a large propor-
tion of plasma cfDNA is found within exosomes. Further research is 
required to understand the biological differences between cfDNA 
and nExos, which may be minimal due to the potential overlap 
between them.
Our findings suggest that genotoxic drugs induce MN formation 
and nExo release. In this study, we used topotecan and olaparib 
because of their direct effects on DNA repair mechanisms (29, 30). 
Although both drugs have different mechanisms for targeting 
cancer cells, both can induce genomic instability and induce apoptosis. 
MN serve as a marker of genomic instability, and they form either 
by chromosome mis-segregation during mitosis or from direct insults 
to gDNA (31). Our in vivo mouse experiments revealed a trend toward 
an increased number of micronucleated cells in the topotecan- 
treated group, but this difference was not statistically significant, 
which may reflect the single dose of topotecan used for this experiment. 
In addition, we observed a significant increase in the concentration 
of nExos in the ascites of tumor-bearing mice, but not in the serum. 
This difference may be due to an insufficient dose of the drugs, a 
small sample size, or a larger fraction of tumor-derived exosomes in 
ascites compared to serum.
The observation that the nuclear envelope of MN is unstable 
and prone to collapse, exposing its contents to the cell cytoplasm, 
prompted the idea that this event allows nuclear content to be loaded 
into exosomes (13). As described in previous sections, tetraspanins 
play a role in shuffling content into MVBs, which eventually gives 
rise to the secreted exosomes (3). In this study, we observed that 
CD63 surrounds the MN envelope and loads nuclear contents into 
exosomes. The role of CD63 in exosome cargo loading is further 
supported by a recent finding that CD63 interacts with the RNA bind-
ing protein, Y-box protein I, to load miR-223 into exosomes (32). 
To our knowledge, CD63 does not contain a canonical DNA bind-
ing domain. For this reason, we hypothesize that CD63 may interact 
with DNA binding proteins, such as histones, to indirectly load gDNA 
into exosomes. The presence of a complex containing CD63–Histone 
H2B–gDNA in our experiments suggests that this could play an im-
portant role in the loading of DNA into exosomes, but elucidating 
the dynamics and all the players involved in this process requires 
additional work beyond the scope of this current study.
Despite the growing interest in exosome biology, little is known 
about the biological function of nExos. Recently, Takahashi et al. (8) 
reported that gDNA is present in exosomes and that inhibiting 
total exosome secretion promotes cell senescence by stimulating 
the cGAS/STING inflammatory pathway. In recipient cells, it was 
demonstrated that T cell–derived extracellular vesicles containing 
genomic and mitochondrial DNA induced antiviral responses via 
the cGAS/STING cytosolic DNA–sensing pathway in dendritic cells 
(33). In addition, it is known that MN can promote the activation of 
the cGAS/STING pathway, resulting in an inflammatory response 
in both senescent and cancer cells (14, 34).
Chromosomal instability has been observed to correlate with tumor 
metastasis, and a recent report suggested that this may be mediated by 
a cytosolic DNA response (34). Inflammation is a key inducer of cancer 
progression by creating a nourishing tumor microenvironment (35). 
In this context, it is not surprising that the secretion of nuclear content 
by cancer cells via exosomes may promote metastasis by promoting a 
proinflammatory environment. Further research is required to fully 
elucidate the role of nExos in modulating the tumor microenvironment.
It has been reported that plasma-derived exosomal DNA does 
not fully represent tumor CNV status due to the low concentration 
of tumor-derived exosomes (36). Consistent with this observation, 
our data showed that plasma-derived exosomes did not carry enough 
gDNA to obtain WGS libraries of sufficient complexity for accurate 
detection of CNV or single-nucleotide variation (SNV) (Fig. 6I and 
fig. S6). However, our data demonstrate that ascites-derived exo-
somes represent tumor CNV status. It is possible that the plasma 
exosome libraries show lower depth of coverage than the ascites 
exosomes or tumor. Several mutations related to DNA repair were 
found in matched tumor and ascites exosome DNA. Exploring the 
role of these genes and their potential for prediction of sensitivity 
or resistance to poly(adenosine diphosphate–ribose) polymerase 
(PARP) inhibitors in ovarian cancer remains to be determined. These 
findings suggest that ascites nExos rather than serum nExo can be a 
reliable biomarker source to probe the tumor genome. This is partic-
ularly important in HGSC where distinct CNV signatures can serve 
as predictors of treatment response and ultimately clinical outcome 
(37). The ability to quickly isolate and probe ascites nExo CNV may 
allow clinicians to optimize therapy regimens without the direct 
biopsy of tumors. Future studies must be done to understand 
whether CNV in ascites nExo directly correlates with CNV responses 
in ovarian cancer tumors and affects patient clinical outcomes.
Overall, our study provides the foundation for understanding the 
cellular mechanisms of nuclear content loading into exosomes and 
their potential biological functions. Moreover, to translate these 
findings in the clinic, further validation is needed for the use of 
nExo as biomarkers of clinical response and outcomes. The use of 
the described imaging flow cytometry method can monitor changes 
of nExos from patients who are either resistant or sensitive to geno-
toxic drugs. This is particularly important for ovarian cancer patients 
given the recent U.S. Food and Drug Administration (FDA) approval 
of olaparib and other PARP inhibitors for this cancer type.
MATERIALS AND METHODS
Pan-cancer TCGA ploidy analysis
Ploidy data from TCGA samples were downloaded from the Pan- 
Cancer TCGA project (https://www.cell.com/pb-assets/consortium/
pancanceratlas/pancani3/index.html; accessed 8 September 2016).
Cell lines and tissue culture
The human ovarian cancer cell lines were obtained from the American 
Type Culture Collection (ATCC) and the University of Texas MD 
Anderson Cancer Center Characterized Cell Line Core Facility. Cell 
lines were routinely identified via short tandem repeat DNA profiling 
carried out by the Characterized Cell Line Core Facility at MD 
Anderson. Primary FTE cells were a gift from J. Liu from the Depart-
ment of Pathology at MD Anderson. For all cell lines, mycoplasma 
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testing was done using the ATCC PCR Universal Mycoplasma Detec-
tion Kit (30-1012K). OVCAR-8 cells were cultured in HyClone 
RPMI 1640 medium (SH30027.01, GE Healthcare Life Sciences) 
supplemented with 15% fetal bovine serum (FBS) (Sigma-Aldrich) and 
0.2% gentamicin (50146970, Thermo Fisher Scientific). OVCAR-5 cells 
were cultured in Dulbecco’s modified Eagle’s medium (DMEM; 
10-013-CV; Corning) supplemented with 10% FBS and 0.2% genta-
micin. FTE cells were cultured in medium 199 with MCDB 105 (1:1) 
with 10% FBS and 0.2% gentamicin. All cells were grown in humidi-
fied incubators kept at 37°C with 5% CO2.
Isolation of exosomes
The isolation method for exosomes that was used in this study fol-
lowed the standard methods of the International Society of Extra-
cellular Vesicles (38). Cell lines described above were grown in the 
corresponding medium described above until 60 to 70% confluence 
was achieved. Cells were then washed twice with phosphate-buffered 
saline (PBS) and grown in corresponding medium containing 1% 
exosome-free FBS (EXO-FBS-250A-1, System Biosciences) plus 
0.1% gentamicin for 48 hours. For exosome isolation, the harvested 
medium underwent serial centrifugation. First, the medium was 
spun down at 500g for 10 min to pellet any floating cells. Next, the 
supernatant was collected and spun down at 2000g for 30 min to 
pellet any residual cell debris. The resulting supernatant was then 
filtered through a 0.22-m filter (SCGPU05RE and SLGP033RS, 
Millipore-Sigma) to remove any remaining large vesicles. After filtra-
tion, the medium was spun down at 40,000 rpm for 2 hours at 4°C 
in an ultracentrifuge (Optima XE, Beckman Coulter) with a Ti 45 
fixed-angle rotor (339160, Beckman Coulter). The resulting exo-
some pellet was resuspended in 2 ml of PBS and then spun again 
at 40,000 rpm for 2 hours at 4°C. The final pellet was resuspended 
in PBS and stored at 4°C. Exosome concentration and quantity 
were determined using NTA with a NanoSight NS300 instrument 
(Malvern Panalytical).
Isolation and purification of exosomes from  
patient serum and plasma
To isolate exosomes from serum and ascites obtained from patients 
with ovarian cancer, 200 l of each patient’s serum or ascites sample 
was collected and stored at 4°C. The serum was diluted with an equal 
volume of PBS and then centrifuged at 2000g for 30 min at 4°C. The 
supernatant was transferred to clean tubes without disturbing the pellet 
and centrifuged at 12,000g for 45 min at 4°C. The supernatant was 
then transferred to fresh tubes and diluted with a large volume of PBS 
(about 3 ml). After filtration with a 0.22-m filter, the supernatant was 
transferred to ultracentrifuge tubes and ultracentrifuged at 40,000 rpm 
for 2 hours at 4°C as described above. The supernatant was then dis-
carded, and the exosome pellet was resuspended in 3 ml of PBS. This 
was followed by another 40,000 rpm ultracentrifugation spin for 
70 min at 4°C. The final pellet was resuspended in PBS. To further 
purify patient-derived exosomes from abundant protein aggregates 
present in both serum and ascites, we used size exclusion chroma-
tography as described previously (21). Exosome-enriched fractions 
were identified by both NTA and SDS–polyacrylamide gel electro-
phoresis (SDS-PAGE) methods (fig. S5, A to D).
Exosome staining for imaging flow cytometry and analysis
For quantitative analysis and imaging flow cytometry of exosomes, 
we adapted the method described by Erdbrugger et al. (16) using an 
Amnis ImageStreamX MarkII analyzer. Briefly, 3 × 109 to 5 × 109 
particles were isolated from either tissue culture cells, mouse serum 
and ascites, or serum obtained from patients with ovarian cancer 
and resuspended in PBS. Exosomes were placed in a sterile 1.5-ml 
Eppendorf tube and stained with CellMask Green Plasma Membrane 
(CMG) stain (1:250 dilution; C37608, Thermo Fisher Scientific ) for 
30 min at 37°C, protected from light. Exosomes were then washed 
to remove excess CMG by adding 2 ml of PBS and pelleted by ultra-
centrifugation at 40,000 rpm for 2 hours at 4°C. The supernatant 
was discarded, and the exosome pellet was gently resuspended in 
100 to 150 l of PBS. For antibody staining of exosomes, CMG-stained 
exosomes were incubated with fluorophore-conjugated primary 
antibodies described below for 1 hour with gentle agitation at room 
temperature (RT), protected from light. After 1 hour, the exosomes 
were washed by placing them in 2 ml of PBS and pelleting them by 
ultracentrifugation at 40,000 rpm for 2 hours at 4°C. The resulting 
pellet was then resuspended in 100 to 150 l of PBS.
To stain for dsDNA, CMG-stained exosomes were costained with 
DRAQ5 (62254, Thermo Fisher Scientific) at either 1:50 dilution for 
biofluid exosome samples or 1:250 dilution for cell culture samples 
and were lightly agitated at RT for 1 hour, protected from light. 
Samples were then placed on ice, and images of single exosomes were 
detected using the 60× objective of an Amnis ImageStreamX MarkII 
analyzer. The ImageStream was equipped with five lasers [200 mW 
405 nm, 100 mW 488 nm, 200 mW 561 nm, 150 mW 642 nm, 70 mW 
785 nm (SSC)], and all lasers were used at maximum power with the 
instrument set for 7 m core diameter (low speed). Particle size was 
estimated using Invitrogen Flow Cytometry Sub-micron Particle 
Size Reference Beads (F13839, Thermo Fisher Scientific), allowing 
exclusion of particles <150 nm based on the signal detected from side 
scatter. Controls for all exosome analyses included detergent lysis 
controls, buffer controls without exosomes, reagents alone in buffer, and 
antibody-unstained samples. For detergent lysis controls, samples were 
incubated for 30 min at RT after adding the nonionic detergent NP-40 
to a final concentration of 0.5%. All analyses, including gate placement 
and batch processing, were performed using the Amnis proprietary 
IDEAS and INSPIRE software packages at the South Campus Flow 
Cytometry and Cell Sorting Core, the University of Texas MD Anderson 
Cancer Center Flow Cytometry and Cellular Imaging Core Facility.
Antibodies included the CD9 V450 mouse anti-human (1:100; 
561326, BD Biosciences), Nesprin-2 (1:100; MA5-18075, Thermo 
Fisher Scientific) conjugated to Alexa 594, Lamin A/C 636 (SC-7292, 
Santa Cruz Biotechnology) conjugated to Alexa 594, Lamin B1 (1:100; 
8982, Abcam), and Importin (1:100; ab2811, Abcam) conjugated 
to Alexa 594. Conjugation of antibodies for Nesprin-2, LaminB1, 
and importin to Alexa fluorophores was performed by using the 
Molecular Probes Antibody Labeling Kit (A20185 and A20181, 
Thermo Fisher Scientific).
IF experiments and MN quantification
Cells were plated at a density of 5 × 104 cells on sterile, 0.17-mm-thick 
coverslips (12-548-A, Thermo Fisher Scientific) placed at the bottom 
of six-well plates. The next day, cells were treated for 24 hours with 
either vehicle control dimethyl sulfoxide (DMSO; 1:1000 dilution; 
D2650, Sigma-Aldrich), 20 M olaparib (O-9201, LC Laboratories), 
or 10 nM topotecan (T2705-50MG, Sigma-Aldrich). After 24 hours, 
the cells were washed with PBS and refed with the appropriate cell 
culture medium to grow for another 48 hours, for a total time of 
72 hours after initial plating on the coverslips.
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The drug-treated cells were first washed three times with PBS, 
fixed with 4% paraformaldehyde (PFA; 50-980-487, Thermo Fisher 
Scientific) diluted in PBS, and incubated at RT for 15 min with light 
rocking. The PFA was discarded, cells were washed three times 
with PBS, and then incubated for 10 min at RT with 30 mM glycine 
(BP381-5, Thermo Fisher Scientific) diluted in PBS to quench any 
residual PFA. Next, the cells were washed three times with PBS 
and incubated with 0.2% Triton X-100 (BP151-500, Thermo Fisher 
Scientific) diluted in PBS for 10 min at RT with light shaking. Triton 
was discarded, and cells were placed in blocking buffer (10% goat 
serum and 1% bovine serum albumin in PBS, syringe-filtered with 
0.22-m filter) for 1 hour at 4°C. Cells were next incubated over-
night at 4°C with Lamin A/C (1:1000; ab26300, Abcam and 1:200; 
sc-5275, Santa Cruz Biotechnology), CD63 (1:1000; ab1318, Abcam), 
EEA1 (1:500; ab109110, Abcam), LAMP1 (1:100; ab108597, Abcam), 
and LC3B (1:200; ab64781, Abcam) antibodies diluted in blocking 
buffer. After primary antibody incubation, cells were washed 
three times with PBS and incubated with secondary antibodies 
Alexa Fluor 488 goat anti-mouse immunoglobulin G (IgG) (1:200; 
115-545-003, Jackson ImmunoResearch) and Alexa Fluor 596 goat 
anti-rabbit (1:200; 111-586-047, Jackson ImmunoResearch) as well 
as DAPI (1:1000; D9542-1MG, Sigma-Aldrich) diluted in blocking 
buffer and incubated for 30 min at RT while protected from light. 
Last, cells on coverslips were then washed four times with PBS 
and mounted on slides using ProLong Diamond Antifade Mountant 
(P36961, Thermo Fisher Scientific) and imaged with a Leica fluores-
cence microscope (Leica DM4000 M LED; Leica Microsystems) or 
an Andor Revolution XDi WD Spinning Disk Confocal microscope. 
For MN quantification, we counted the number of MN in each 40× 
field using 10 fields per sample.
Confocal imaging
Cells were plated at a density of 2 × 104 cells onto glass coverslips in 
six-well plates, placed back into the incubator, and allowed to grow 
for 48 to 72 hours. The growth medium was removed, and the cells 
were washed once with PBS and subsequently fixed with 3.7% form-
aldehyde for 15 min at RT. Cells were then permeabilized with 0.1% 
Triton X-100 for 5 min, washed two times, and blocked with 10% 
normal goat serum for 1 hour at 37°C. Primary antibodies CD63 
(ab1318, Abcam), CD9 (ab97999, Abcam), CD81 (ab35026, Abcam), 
and Lamin A (ab26300 and ab8980, Abcam) were diluted in 1% 
normal goat serum and applied for 2 hours at 37°C. Primary anti-
bodies were removed, cells were washed three times for 5 min with 
PBS, and incubated with Alexa-conjugated secondary antibodies 
diluted in Dulbecco's PBS for 1 hour at 37°C. Secondary antibodies 
were removed, coverslips were washed three times for 5 min, and 
mounted onto glass slides using Vectashield Hardset with DAPI 
(H-1500, Vector Labs). Images were acquired using a Zeiss LSM 
710 confocal microscope with a 63× objective.
Western blotting
For Western blotting, harvested cells and exosomes were lysed with 
radioimmunoprecipitation assay buffer (RIPA) [25 mM tris (pH 7.5), 
150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton 
X-100] supplemented with single-use phosphatase and protease 
inhibitors (78442, Thermo Fisher Scientific). Protein concentration 
was determined using the Micro BCA Protein Assay Kit (23235, 
Thermo Fisher Scientific) according to the manufacturer’s protocol. 
For all Western blots, we used 5 to 10 g of total cell or exosome 
lysate diluted with 2× Laemmli sample buffer (1610737, Bio-Rad), 
which was loaded onto 10% SDS denaturing polyacrylamide gels. 
Protein was transferred to a nitrocellulose membrane, blocked with 
5% nonfat dry milk (AB10109-01000, AmericanBio) in tris-buffered 
saline with 0.1% Tween 20 (TBS-T) for 1 hour at RT, and incubated 
with the indicated antibodies diluted in 5% milk in TBS-T overnight 
at 4°C with light agitation. The next day, the membrane was washed 
three times with TBS-T for 10 min with light agitation. After the 
third wash, the membrane was incubated with species-specific sec-
ondary antibodies conjugated to horseradish peroxidase (NA931V 
and NA934V; GE Healthcare) and diluted 1:2500 in 5% milk in 
TBS-T for 1 hour at RT with light agitation. The membrane was then 
washed three times in TBS-T and finally developed using Western 
Lightning Plus ECL (NEL105001EA; PerkinElmer) on x-ray film 
(F-BX57, Phenix). For reprobing of Western blots, membranes were 
stripped with Restore PLUS Western Blot Stripping Buffer (46430, 
Thermo Fisher Scientific), reblocked in 5% milk TBS-T, and incu-
bated with primary antibody. In this study, we used the following 
primary antibodies and dilutions: CD63 (1:3000; EXOAB-CD63A-1, 
System Biosciences), TSG101 (1:500; ab30871, Abcam), Alix (1:500; 
SC-53538, Santa Cruz Biotechnology), GRP94 (1:500; SC-393402, 
Santa Cruz Biotechnology), Lamin A (1:1000; ab26300, Abcam), and 
Histone H2B (1:500; ab1790, Abcam).
Plasmid transfections
For transient transfection of cells for live cell imaging, we used a 
method that was similar to the one described above with some 
modifications. Briefly, cells were plated at a density of 3 × 105 to 4 × 
105 cells per six-well plate so that cells reached 90% confluence the 
next day. For transfections, Lipofectamine 2000 (11668500, Thermo 
Fisher Scientific) was complexed with 1 g of the plasmid mEmerald- 
CD9-10 (54029, Addgene), as described above. At 48 hours after 
transfection, mEmerald-CD9 expression was verified by using fluo-
rescent microscopy, and cells were used for subsequent live cell 
imaging experiments.
Cloning of mCherry-LaminA/C into a lentiviral vector
The mCherry-LaminA/C fusion protein was cloned from the parental 
plasmid mCherry-LaminA-C-18 (55068, Addgene) using restriction 
enzyme digestion with Nhe I (FD0973, Thermo Fisher Scientific) 
and Bam HI (FD0054, Thermo Fisher Scientific). The parental 
lentiviral vector pCDH-CMV-MCS-EF1-Puro (CD510B-1, System 
Biosciences) was also digested with Nhe I and Bam HI. One micro-
gram of each parental plasmid was used for the restriction enzyme 
digestions. Digestion products were run on a 1% agarose gel made 
with 1× TBE buffer (1.0 M tris, 0.9 M boric acid, and 0.01 M 
EDTA; 15581-028, Invitrogen UltraPure). The desired digestion 
products were cut and gel-purified using the GeneJET Gel Extraction 
Kit (K0692, Thermo Fisher Scientific) according to the manufac-
turer’s protocol. mCherry-LaminA/C was ligated into pCDH-CMV- 
MCS-EF1-Puro using T4 ligase (M0202S, NEB) for 12 hours at 
16°C according to the manufacturer’s protocol. The ligation product 
was transformed into NEB Stable Competent Escherichia coli 
(C3040I, NEB) according to the NEB protocol, plated on ampicillin 
plates, and grown at 37°C for 12 hours. Colonies were picked and 
grown in LB medium at 37°C (12795027, Thermo Fisher Scientific) 
supplemented with ampicillin (BP1760-5, Fisher BioReagents). 
Plasmid DNA was purified using the Qiagen Plasmid Plus Midi Kit 
(12945) according to the manufacturer’s protocol.
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Lentiviral production and cell transduction
For lentiviral production, human embryonic kidney (HEK) 293T cells 
(grown in DMEM, 10% FBS, and 0.2% gentamicin) were transfected 
using Lipofectamine 2000 (11668500, Thermo Fisher Scientific) with 
10 g of lentiviral plasmid (see below for plasmids used), along with 
5 g of psPAX2 (12260, Addgene) and 2.5 g of pMD2.G (12259, 
Addgene) lentiviral helper plasmids. Cell medium containing newly 
generated virus was collected 48 and 72 hours after transfection, 
pooled, centrifuged to clear any cell debris, and syringe-filtered using 
a 0.45-m filter (190-2545, Thermo Fisher Scientific). For infection, 
cells were plated at 50% confluence in six-well plates and incubated 
with 2 ml of newly produced virus along with polybrene at a 1:1000 
dilution (sc-134220, Santa Cruz Biotechnology) for 24 hours. Cells 
were then refed with regular medium and allowed to grow. The cells 
with vectors containing drug selection markers such as puromycin 
(A11138-03, Gibco) were exposed to puromycin for 48 hours after 
initial lentiviral infection. Surviving cells were expanded and used 
for subsequent in vitro and in vivo experiments. Lentiviral vectors 
used in this study included pCDH-CMV-MCS-EF1-Puro-mCherry- 
LaminA/C (see previous section), pCT-CD63-GFP (CYTO120-VA-1, 
System Biosciences), pLenti6-H2B-mCherry (89766, Addgene), and 
pLKO-CD63shRNA (SHCLNV-NM_001780, Sigma-Aldrich). For 
shRNA sequences, two different target sequences for human CD63 
were used: (i) 5′-CCGGGCCTCGTGAAGAGTATCAGAACTC-
GAGTTCTGATACTCTTCACGAGGCTTTTT-3′ and (ii) 5′-CCG-
G G C A A G G A G A A C T A T T G T C T T A C T C G A G T A A G A -
CAATAGTTCTCCTTGCTTTTT-3′. The nontargeting shControl 
5′-CCGGCCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGGG-
CGACTTAACCTTAGGTTTTTG-3′ was used.
Luciferase labeling of OVCAR-5 cells
To label cells with luciferase for in vivo imaging system (IVIS) imag-
ing, cells were infected with the lentiviral vector pGreenFire1-CMV 
(TR011PA-1, System Biosciences), which coexpresses green fluo-
rescent protein (GFP). Cells were sorted using FACSAria IIIu at the 
South Campus Flow Cytometry and Cell Sorting Core, MD Anderson 
Flow Cytometry and Cellular Imaging Core Facility for GFP positivity.
In vivo experiments
For the in vivo mouse experiments, female athymic (NCr-nude) mice 
were purchased from Taconic Biosciences. Mice were cared for in 
accordance with the American Association for Assessment and 
Accreditation of Laboratory Animal Care and the U.S. Public Health 
Service policy on Humane Care and Use of Laboratory Animals. All 
studies and experiments that were performed were supervised and 
approved by the MD Anderson Institutional Animal Care and Use 
Committee. Mice were 10 to 15 weeks old at the time of tumor intra-
peritoneal cell injections. OVCAR-5 luciferase–labeled cells (1 × 106) 
were injected intraperitoneally into each mouse.
Injected cells were first grown in the indicated medium until they 
reached 70% confluence. The cells were then trypsinized (SH30042.01, 
GE Healthcare), washed twice with PBS, and resuspended in ice-cold 
Hanks’ balanced salt solution (21-021-CV; Cellgro). To determine 
tumor cell uptake, mice were injected with 200 l of luciferin (14.7 mg/ml) 
(LUCK-1G; GoldBio) and imaged using IVIS. Non–tumor-bearing 
mice were removed from the experiment. Mice were randomly assigned 
to the treatment groups. We conducted all in vivo experiments, and 
the primary investigator was not blinded to the allocation of each 
treatment group. At the end of the experiment, blood and ascites 
were collected from each tumor-bearing mouse, and exosomes were 
isolated.
Enrichment of MN fractions
Methods for isolation and purification of cultured cell MN were 
adapted from Damaraju et al. (19) with the following modifications: 
Harvested OVCAR-5 cells were scraped from 15-cm tissue cultures 
using ice-cold PBS supplemented with protease and phosphatase 
inhibitors and pelleted by centrifugation at 500g for 10 min at 4°C.
The supernatant was carefully discarded, and the cell pellet was gently 
resuspended in 1 ml of ice-cold cell lysis buffer obtained from the 
Active Motif ChIP-IT Express Chromatin Immunoprecipitation Kit 
supplemented with protease and phosphatase inhibitors provided 
by the kit (53008, Active Motif). Cells were incubated in lysis buffer 
on ice for 30 min and then carefully pipetted into a 1-ml Dounce 
homogenizer. We used 20 to 25 strokes in the Dounce homogenizer 
to release intact cell nuclei from the rest of the cell components. To 
ensure successful cell lysis, a small aliquot of the cell suspension was 
stained with DAPI (1:1000) and imaged with our fluorescence 
microscope (Fig. 4A). Lysed cells were then spun at 2400g at 4°C to 
pellet cell nuclei. Supernatant from this step, which contained MN, 
was kept, and pelleted cell nuclei were discarded. Cell supernatant 
was loaded to a sucrose gradient (84097-1KG, Sigma-Aldrich) pre-
pared in PBS by using fractions indicated by Damaraju et al. (19). 
The fraction corresponding to 25% sucrose was collected and mixed 
with an equal volume of ice-cold PBS. The fraction was centrifuged 
at 13,500g at 4°C to pellet the MN, the supernatant was discarded, 
and MN were resuspended in ice-cold PBS with protease and phos-
phatase inhibitors. To confirm the presence of MN, an aliquot of the 
suspension was stained with DAPI and analyzed with a fluorescence 
microscope (Fig. 3A). The purified fraction was either sent for MS 
analysis or stored at −80°C.
Immunoprecipitation experiments
For IP analysis, whole-cell lysates were extracted following the 
manufacturer’s protocol provided by the Universal Magnetic Co-IP 
Kit (54002, Active Motif), and 1000 g of protein was immunopre-
cipitated using 2.5 g of antibody. The prepared samples were used 
for Western blot and DNA staining by agarose gel electrophoresis.
DNase I treatment
Samples were treated with DNase I (1 unit/l; E1011-A, Zymo 
Research) with DNase digestion buffer (E1011-1-4, Zymo Research) 
and incubated at 37°C for 45 min. Subsequently, 5 l of EDTA solu-
tion (1861274, Thermo Fisher Scientific) was added, and the sam-
ples were heated at 65°C for 5 min.
Human tumor samples and MN quantification
High-grade ovarian tumor samples were obtained from MD Anderson 
Tissue Bank under an approved institutional review board protocol, 
and written consent was obtained for the use of patient samples for 
research. The details regarding the quality control for the samples 
obtained from CHTN can be found at https://www.chtn.org/quality.html. 
For MN identification and quantification, the Vectra Polaris platform 
(PerkinElmer) was used, and inForm software (PerkinElmer) was used 
to systematically count MN. After tissue segmentation, a number of 
nuclei in views were calculated by the cell segmentation process, and 
MN was defined as over 0.85 roundness and less than approximately 
3 m size (95 pixels in 96 dpi images), as shown in Fig. 3D.
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Time-lapse cell imaging
Fluorescently labeled cells were plated onto sterilized four-chamber 
0.170-mm glass-bottom slides (80427, Ibidi) at a density of 1 × 104 
cells per well. The following day, cells were imaged with an Andor 
Revolution XDi WD Spinning Disk Confocal microscope on a 
humidified stage, which was kept at 37°C with 5% CO2 to simulate 
optimal growing conditions. Hepes (10 mM) (25-060-Cl; Corning) 
buffer was added to the culture medium before imaging to maintain 
a stable pH throughout imaging. Cells were imaged every 5 min 
for movie S1 and every 10 min for movie S2 using a 63× silicon 
immersion objective lens for 12 hours. Images and movies were 
anal yzed with Imaris Image Analysis Software (Bitplane, Oxford 
Instruments). For labeling of cell membranes, CellMask Deep Red 
(C10046, Thermo Fisher Scientific) was used according to the man-
ufacturer’s protocol.
Electron microscopy
Cells were prepared in the following manner: 2.5 × 104 OVCAR-5 cells 
were plated on plastic 24-well tissue culture plates. Forty-eight hours 
later, cells were washed three times with PBS and fixed with 4% PFA 
with 0.1% of glutaraldehyde (G7651-10ML, Sigma-Aldrich) diluted 
in PBS, which was 0.22 m syringe-filtered for 15 min at RT. Cells 
were then washed three times with PBS, and 2% glutaraldehyde was 
added to each well of cells. Twenty-four–well plate was then kept at 
4°C until ready for TEM processing at the MD Anderson Cancer 
Center High Resolution Electron Microscopy Facility. Samples were 
fixed with a solution containing 3% glutaraldehyde plus 2% PFA in 
0.1 M cacodylate buffer (pH 7.3), then washed in 0.1 M sodium 
cacodylate buffer and treated with 0.1% Millipore-filtered cacodylate- 
buffered tannic acid, postfixed with 1% buffered osmium, and 
stained en bloc with 1% Millipore-filtered uranyl acetate. The sam-
ples were dehydrated in increasing concentrations of ethanol and 
then infiltrated with and embedded in LX-112 resin. The samples 
were polymerized in a 60°C oven for approximately 72 hours. Ultrathin 
sections were cut in a Leica Ultracut microtome (Leica, Deerfield, IL), 
stained with uranyl acetate and lead citrate in a Leica EM stainer, 
and examined in a JEM 1010 transmission electron microscope 
(JEOL, USA Inc., Peabody, MA) at an accelerating voltage of 80 kV. 
Digital images were obtained using the AMT Imaging System 
(Advanced Microscopy Techniques Corp., Danvers, MA).
For cryo-EM, 1 × 1010 to 5 × 1010 exosomes were isolated from 
either ovarian cancer cells or patient plasma and ascites and resus-
pended in 50 l of PBS. The samples were prepared for cryo-EM 
studies at the Baylor College of Medicine Cryo-Electron Microscopy 
Core Facility (BCM, Houston, TX). The grids (Quantifoil R2/1, Cu 
200 mesh) were pretreated with a 45-s air-glow discharge immedi-
ately before vitrification. During vitrification, 3 l of exosome sam-
ple was applied to a grid, blotted for 4 s, and subsequently plunged 
into liquid ethane using Vitrobot Mark IV (FEI Company, Hillsboro, 
OR) set at RT and 100% humidity. The frozen grids were then im-
aged using a JEOL 2200FS microscope (JEOL) fitted with a post- 
column energy filter with a width of 30 eV. Before imaging, the 
microscope was carefully aligned to prevent any column-based distor-
tion or astigmatism that can occur. Images were collected at magni-
fications of 25,000× and 40,000× with respective pixel sizes of 2.51 
and 1.64 Å using a DE-20 camera (Direct Electron, San Diego, CA). 
Imaging was done with a dose rate of ~30e−/Å2/s using a 1-s exposure 
time with a capture rate of 24 frames/s. Gain and dark corrections 
were applied automatically to produce the final images used.
MS analysis
A total of about 20 to 40 g of intact isolated exosomes from either 
OVCAR-5 cells or patient samples in addition to 40 g of OVCAR-5 
were quantified using the Micro BCA Protein Assay Kit (23235, 
Thermo Fisher Scientific) and sent to the MD Anderson Mass Spec-
trometry core. Proteins were acetone-precipitated (5:1) overnight 
at −20°C and digested with 200 to 500 ng of modified trypsin (se-
quencing grade; Promega, Madison, WI) in the presence of RapiGest 
(Waters, Milford, MA) for 18 hours at 37°C. The resulting pep-
tides were analyzed by high-sensitivity liquid chromatography–MS/
MS on an Orbitrap-Fusion mass spectrometer (Thermo Fisher 
Scientific, Waltham, MA). Proteins were identified by searching 
the fragment spectra in the SwissProt (EBI) protein database using 
Mascot (version 2.6.2; Matrix Science, London, UK). Typical search 
settings were mass tolerances: 10 ppm (parts per million) precursor, 
0.8d fragments; variable modifications, methionine sulfoxide, 
pyro- glutamate formation; up to two missed cleavages. False dis-
covery rate estimates were from Proteome Discoverer (version 2.2, 
Thermo Fisher Scientific).
Library preparation and sequencing
Exosome DNA was isolated from 1 × 1010 to 5 × 1010 exosomes from 
either tissue culture cells or bodily fluids with the System Biosciences 
XCF Exosomal DNA Isolation Kit (XCF200A-1, Systems Biosciences) 
following the manufacturer’s protocol. gDNA from either cultured 
cells or tumor tissue was isolated using the Qiagen DNeasy Blood 
and Tissue Kit (69506, Qiagen) according to the manufacturer’s 
protocol. DNA concentration was determined using both the 
NanoDrop 2000 Spectrophotometer (Thermo Fisher Scientific) and 
the Agilent 2100 Bioanalyzer Kit (5067-150, Agilent Technologies) 
following the manufacturer’s protocol.
WGS next-generation sequencing (NGS) libraries were constructed 
either using the KAPA HyperPlus Kit (Roche Holding AG) or the 
Zymo Pico Methyl-Seq Kit (Zymo Research), depending on the 
source of the DNA sample. The KAPA kit provides a relatively un-
biased enzymatic fragmentation method, which allows balanced 
coverage and low-input polymerase chain reaction (PCR)–free DNA 
NGS library construction (39). dsDNA (Onco-NoPCR) (300 ng) in 
0.5 mM EDTA was added with the appropriate amount of condition-
ing solution to the enzymatic fragmentation step. The dsDNA was 
then incubated with the fragmentation enzyme for 6 min at 37°C. 
The fragmented samples were then end-repaired and A-tailed, and 
Illumina-indexed adapters were ligated onto the ends of the dsDNA. 
A two-sided AmpureXP bead selection protocol (0.55×/0.8× /2.5×) 
was used to select for an average NGS library size of approximately 
481 base pairs (bp).
The Zymo kit protocol is a post-bisulfite adapter tagging NGS 
library protocol and is relatively unbiased as a hybridization-based 
NGS library generation method. This protocol was modified to 
exclude the bisulfite DNA fragmentation step, extend the initial 
adapter tagging extension step from 8 to 30 min, and extend the two 
PCR extension steps from 1 to 6 min. ExDNA (extracellular DNA) 
(100 ng) was used to generate a NGS library with this Zymo kit. Six 
cycles of PCR were used during the final index adapter addition step. 
A two-sided AmpureXP bead selection protocol (0.55×/0.8× /1.2×) 
was used to select for an average NGS library size of approximately 
473 bp.
The NGS libraries were quantified using a PicoGreen-based assay 
(Qubit, Thermo Fisher Scientific), and for quality control purposes, 
Yokoi et al., Sci. Adv. 2019; 5 : eaax8849     20 November 2019
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
15 of 16
their size distribution profiles were determined using a Bioanalyzer 
instrument (Agilent Technologies Inc.) The NGS libraries were then 
sequenced on a NovaSeq 6000 instrument (Illumina, San Diego, CA) 
using paired-end 2 × 150–bp reads (UCSF Functional Genomics Core, 
University of California, San Francisco, San Francisco, CA) or a HiSeq 
4000 instrument (Illumina, San Diego, CA) using paired-end 2 × 
100–bp reads (IGM Genomics Center, University of California, 
San Diego, La Jolla, CA).
Bioinformatics analysis
Regarding cell line samples, the fastq files were first quality-controlled 
using FastQC (version 0.11.4) and adapters were trimmed using 
Trim Galore (version 0.4.1). The trimmed fastq files were then mapped 
to GRCh38 (GCA_000001405.15) using Bowtie2 (version 2.2.7) (40) 
and duplicated, sorted, and indexed using Samtools (version 1.3). 
The OncoNoPCR sample was sequenced to an average depth of 23×, 
and the ExDNA was sequenced to an average depth of 20×. Copy num-
ber alterations were called using cnvkit-0.9.6a0-py27_2. The batch WGS 
method was used after calculating the sequence-accessible coordinates 
from the reference genome. CNVs were then called using the follow-
ing command: cnvkit.py batch --method wgs *sort.bam -n –f ../
GCA_000001405.15_GRCh38_no_alt_analysis_set.fna --access access- 
excludes.GRCh38.bed --output-reference my_flat_reference.cnn -p 
12 --scatter --diagram -d cnv_data/. Adjacent regions with the same 
copy number calls were merged using the cnvkit.py call –filter option. 
Copy number alterations were considered to be overlapping if they con-
tained at least a 30% reciprocal overlap using Bedtools (version 2.25.0). 
Figures were made using cnvkit’s scatter function and circos-0.69-3.
Regarding clinical samples, fastq files are aligned to the reference 
genome (human Hg19) using Burrows-Wheeler Alignment tool (BWA) 
with three mismatches, with two in the first 40 seed regions for se-
quences less than 100 bp. The aligned BAM files are subjected to 
mark duplication, realignment, and recalibration using Picard and 
GATK before any downstream analyses. Somatic mutations were 
called using MuTect, and indels were called using Pindel. DNA copy 
number analysis is conducted using HMMcopy following circu-
lar binary segmentation (CBS). DNA from blood cells was used 
as the reference in all of the above analyses. Mutation and indel calls 
were filtered using thresholds of ≥20 reads covering the called event 
for plasma, ascites, or tumor tissues and ≥20 reads for blood cells. 
An allele frequency cutoff of 0.2 was also applied to the mutation 
and indel data.
Statistical analysis
All statistical analyses of in vitro and in vivo experiments were done 
using GraphPad Prism 7 and the SPSS software program (version 24.0, 
IBM Corporation). To determine whether differences between 
the two groups were significant, we used a two-tailed Student’s t test 
(equal variance). For these analyses, a P value of <0.05 was considered 
statistically significant. Results were presented as the mean ± SD.
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